ABSTRACT
Locus coeruleus activity was monitored by either in vivo electrochemistry, post-mortem HPLC, or single unit activity, after systemic administration of RU 24969, a potent serotonin-1 agonist. Whatever the methodology, activation of the locus coeruleus appeared after RU 24969 injection. Catechol oxidation current, assessed by in vivo differential pulse voltammetry and single unit activity in the locus coeruleus showed simultaneous increases after RU 24969. The increase in catechol oxidation current after RU 24969 was dose dependent (ED(50) = 1.4 mg kg(?1) of i.p. RU 24969). This increased activity was also observed on microdissected locus coeruleus as shown by the increased levels of dopamine and 3,4-dihydroxyphenylacetic acid measured with high performance liquid chromatography. Furthermore, RU 24969 treatment decreased 5-hydroxyindolacetic acid/serotonin ratio in the same microdissected locus coeruleus. This increased locus coeruleus catechol metabolic activity was suppressed by making lesions in the serotonergic systems with 5,7-dihydroxytryptamine. By contrast, neither 8-OHDPAT nor methysergide produced significant changes in the catechol oxidation current recorded in the locus coeruleus.
